Replimune to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/11/22
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/03/22
Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of DirectorsGlobeNewsWire • 01/31/22
Replimune Announces Presentations at the 2021 Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingGlobeNewsWire • 10/01/21
Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1GlobeNewsWire • 06/03/21
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/20/21
Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed MelanomaGlobeNewsWire • 05/05/21
Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual MeetingGlobeNewsWire • 04/12/21
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021GlobeNewsWire • 03/11/21
Replimune to Present at the SVB Leerink 10th Annual Global Healthcare ConferenceGlobeNewsWire • 02/18/21